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httpcense.Abstract Body: Settings: The real break-throw in asthma treatment is still unreachable. In many
cases drugs are not effective for reaching the control state. Objectives: To investigate the efﬁcacy of
Carbamazepine in treatment of bronchial asthma.
Patients and methods: A randomized, parallel 6-month trial. Hundred patients fulﬁlled the inclu-
sion criteria and divided into two groups. Group (1) received Carbamazepine (600–1600 mg/day) in
addition to their usual anti-asthmatic treatment and group (2) received only the usual anti-
asthmatic therapy. Baseline electroencephalography (EEG) study was done for all patients. Assessment
of asthma control according to GINA classiﬁcation was done before, 3 and 6 months after therapy.
Results: The mean age of studied patients was (37.9 ± 9.47 and 28.6 ± 11.06), in group 1 & 2
respectively. Two cases in group 1 showed abnormal EEG and no abnormality in group 2. As regards
level of asthma control, there was statistically signiﬁcant difference between ﬁrst visit and third visit in
both groups with high value in group 1 (P value 0.001, 0.04). In comparing spirometric data of both
groups at each visit it revealed statistically signiﬁcant P value in all parameters (FEV1 0.001, FVC
0.003, PEF 0.01, FEF 25–75 0.001) except FEV1/FVC (P value was 0.264). The frequency of acute
asthma exacerbation in both groups was (0.5 ± 0.57 and 3.2 ± 0.98) in group 1 and 2, respectively
(95% CI 2.4–3.1) with highly signiﬁcant P value 0.003. In the Carbamazepine group dizziness was
recorded in 6 cases 12%, itching in 2 cases 4%, and increasing sleepiness in 2 cases 4%.
Conclusion: Carbamazepine is effective in treatment and in achievement of better asthma control
with minimal side effect.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.hoo.com (M.S. Badawy).
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Asthma is one of the commonest diseases in industrialized
countries and there is convincing evidence to suggest that its
prevalence and morbidity are increasing, despite better recog-
nition and increased prescriptions for anti-asthma therapy.
In every 10–12 years the number of patients with asthma dou-
bles and reasons for this are not known [1].is. Production and hosting by Elsevier B.V.
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tients do not lose consciousness, and seizures are localized only
in limited groups of muscles. But patients with bronchial asth-
ma also have spasm of limited groups of muscles in respiratory
tree. In 19th century many physicians called asthma ‘‘bron-
chial seizures’’. Moreover, some patients have aura before
the asthma attacks [2].
Some authors consider asthma as paroxysmal and neuro-
genic inﬂammatory disease. But we know that migraine and
trigeminal neuralgia also are neurogenic inﬂammatory diseases
with paroxysmal clinical picture, Antiepileptic drugs like Car-
bamazepine are highly effective in pharmacotherapy of these
disorders [3]. It is found that in some asthmatic patients who
used antiepileptic drugs for treatment of concomitant trigemi-
nal neuralgia induced signiﬁcant reduction of severity and fre-
quency of asthma attacks [4]. Based on the assumption that
bronchial asthma has not only inﬂammatory, but also certain
neurogenic paroxysmal mechanism and pathophysiological
links with other non-epileptic paroxysmal inﬂammatory dis-
eases – migraine and trigeminal neuralgia, we decided to inves-
tigate efﬁcacy of antiepileptic drug Carbamazepine in patients
with bronchial asthma.
Aim of work: The aim of ths work is to study the efﬁcacy of
the Carbamazepine in patients with bronchial asthma.
Material and methods
The study was conducted in chest diseases and neurology
departments of Qena University Hospital. The duration of
the study was six months, during the period of November
2011 to April 2012. A written consent from all participants
was being taken. The research was to be done only by scien-
tiﬁcally qualiﬁed personnel. All patients’ data were conﬁden-
tially kept as data entry ﬁles without names, with only ID
numbers of the participants. The proposal was to be reviewed
and approved by the ethics committee of the faculty of
medicine.
Hundred asthmatic patients were included and completed
follow up period for 6 months and fulﬁlled inclusion
criteria.
- Patient aged above 16 years; chronic asthmatic patients;
patients with an established (i.e., at least 1 year) clinical his-
tory of asthma.
- Absence of long-term remissions of asthma (lasting more
than 1 month).
- Poorly or partly controlled asthma, due to various reasons,
according to GINA 2010.
- Patients with a FEV1 reversibility of at least 12% from ini-
tial level after 400 mcg salbutamol inhalation.
Exclusion criteria: History or presence of cardiovascular,
renal, neurologic, psychiatric, liver, immunologic, endocrine
diseases.
- Patients with active tuberculosis with indication for
treatment.
- Patients with pulmonary diseases other than bronchial
asthma.
- Patients with known allergy, intolerance/hypersensitivity to
investigational drug.- Patients currently using MAO inhibitors, tricyclic antide-
pressants, antiepileptic drugs, narcotic agents; pregnant or
nursing women.
Patients were subdivided into two equal groups, each group
included 50 patients.
One group received only their usual routine antiasthmatic
therapy according to GINA guideline, while other group re-
ceived Carbamazepine in addition to their usual routine anti-
asthmatic therapy.
Each group was chosen by introducing two closed envelops
to each patient, one of these envelops contained the usual rou-
tine antiasthmatic therapy while the other contained Carbam-
azepine in addition to the usual routine antiasthmatic therapy.
A randomized 6 month trial via each patient chooses one
envelop without telling him about the content of the two envel-
ops and according to the patient’s choice the patient is added
to the corresponding group. The dose of the received Carbam-
azepine is 600–1600 mg/day with gradual introduction [5].
We gave each patient his monthly need of Carbamazepine
in the form of tablets manufactured by Multi Apex-Pharma
Company, each tablet contains 200 mg of Carbamazepine,
and the trade name is Carbapex.
- A careful history was be taken with special emphasis on the
recurrence of the symptoms (cough, wheeze, expectoration,
dyspnoea, etc.), risk factors, family history, other allergic
diseases, therapeutic history and features of the clinical
asthma control. Routine investigations were done with spe-
cial attention to plain chest radiography, pulmonary func-
tion test (PFT) as regards FEV1, FVC, FEV1/FVC, PEF
and FEF 25–75.
- Pulmonary function test (PFT) was done to each patient
before treatment, after three months of treatment and then
after 6 months of treatment. The Micro Lab which is
Mains/battery operated portable electronic spirometer
was used for evaluation of obstruction and its severity
has been determined by standards from the American Tho-
racic Society (ATS) [6]. Outcome effectiveness was assessed
by spirometery measurement, level of asthma control test
(ACT) and emergency room visit.
Electroencephalography (EEG) study was done for all pa-
tients before starting the treatment. EEG was obtained for
all patients using 8 channels Nihon Kohden machine employ-
ing scalp electrode place according to the international 10–20
system with bipolar and referential montages which is recorded
under standard condition with eye closed and with provocative
maneuver as photic stimulation and hyperventilation.
A base line asthma symptoms, features of clinical asthma
control, EEG, PFT as regards FEV1, FEV1/FVC, PEF,
FEF 25–75, assessment of the side effects of Carbamazepine
administration were recorded and then follow up was be done
after 3 and 6 months of treatment.
Statistical analysis: For the statistical analysis of data we
used SPSS for Windows (Release 11.0). We used the paired
Student T-test in correlation between the both groups. P value
60.05 was considered signiﬁcant. Data are presented as mean
+/ Standard Deviation.
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Group 1 (the Carbamazepine group): included 50 patients, 6
males (12%) and 44 females (88%) with their mean age
37.92 ± 9.476, their age ranged between 17–51 years. Group
2 (the routine regular treatment group): included 50 patients,
18 males (36%) and 32 females (64%) with their mean age
28.6 ± 11.062, their age ranged between 16–55 years. In group
(1), 24 cases (48%) had family history of asthma and 26 cases
(52%) had no family history of asthma. In group (2), 28 cases
(56%) had family history of asthma and 22 cases (44%) had no
family history of asthma.
In group (1), 36 cases (72%) had other allergic diseases, 22
cases (44%) of them had allergic rhinitis, 8 cases (16%) of
them had allergic conjunctivitis, 4 cases (8%) of them had ec-
zema and 2 cases (4%) of them had hay fever. While there were
14 cases (28%) who had no other allergic diseases. In group
(2), 14 cases (28%) had other allergic diseases, 10 cases
(20%) of them had allergic rhinitis, 4 cases (8%) of them
had allergic conjunctivitis. While there were 36 cases (72%)
who had no other allergic diseases (Table 1).
The difference between two groups was statistically signiﬁ-
cant P value (0.003).
The electroencephalography results of both groups. In
group (1), the EEG result of 48 cases (96%) was normal and
2 cases (4%) were abnormal. In group (2), the EEG result of
48 cases (96%) was normal and 2 cases (4%) were
uncooperative.
The level of asthma control among group (1) in the ﬁrst vis-
it (pretherapy), after 3 months of treatment (second visit) and
after 6 months of treatment (third visit) is summarized in Ta-
ble 2. The difference between two visits was not statistically
signiﬁcant P value (0.077). In the third visit (after 6 months):
there were 46 controlled cases (92%) including two cases thatTable 1 Other allergic diseases than asthma in studied cases.
Allergic diseases Group (1) Group (2)
No % No %
No allergic disease 14 28 36 72
Allergic rhinitis 22 44 10 20
Allergic conjunctivitis 8 16 4 8
Hay fever 2 4 0 0
Eczema 4 8 0 0
P value 0.003
Table 2 Asthma control level in carbamazepine group comparing I
Carbamazepine cases
1st visit
Number %
Controlled 6 12
Partial controlled 18 36
Uncontrolled 26 52
Total 50 100
P valuehad EEG changes and 4 partial controlled cases (8%). The dif-
ference between the second and the third visits was statistically
signiﬁcant P value (0.001).
The level of asthma control among group 2 (the routine
regular treatment group) in the ﬁrst visit (pretherapy), after
3 months of treatment (second visit) and after 6 months of
treatment (third visit) is summarized in Table 3.
The difference between two groups in the second visit (after
3 months of treatment) as regards level of clinical asthma con-
trol was not statistically signiﬁcant, P value (0.319). The differ-
ence between two groups in the third visit (after 6 months of
treatment) as regards level of clinical asthma control was not
statistically signiﬁcant P value (0.222) (Table 4).
In group (1): 12 cases (24%) showed acute exacerbations
during treatment with mean 1.5 ± 0.57, 2 cases (4%) of them
showed one attack, 6 cases (12%) of them showed two attacks
and 4 cases (8%) showed three attacks. There were 38 cases
(76%) that did not show any exacerbation including 2 cases
that had EEG changes. In group (2): 18 cases (36%) showed
acute exacerbations during treatment with mean 3.2 ± 0.68,
8 cases (16%) of them showed one attack, 4 cases (8%) of them
showed two attacks and 6 cases (12%) showed three attacks.
There were 32 cases (64%) that did not show any exacerbation
with statistically signiﬁcant P value 0.003, Table 5.
The spirometric evaluation, comparison between two
groups in the ﬁrst visit revealed no signiﬁcant difference,
Table 6 while in second and third visits there are statistically
signiﬁcant differences between two groups in all spirometeric
parameters except in mean ratio FEV1/FVC% as shown in
Tables 7 and 8.
The side effects of Carbamazepine administration are sum-
marized in (Table 9). There were 10 cases (20%) that showed
side effects, 4 cases of them (8%) showed dizziness, 1 case
(2%) showed itching, 2 cases of them (4%) showed somno-
lence and 3 cases (6%) of them showed headache.
Discussion
Many authors like term neurosomatic disease, and airways
inﬂammation during asthma also is more neurogenic than im-
mune process. The role of allergies is very important during
asthma, but allergies may be only an initial trigger factor for
neurogenic development of asthma as a chronic disease. Many
authors support the neurogenic character of inﬂammation in
the bronchus during bronchial asthma [7].
Antiepileptic agents are quite effective in therapy of other
non-epileptic paroxysmal disorders, like trigeminal neuralgia
[8] and migraine [9]. Like in asthma, neurogenic inﬂammationst, 2nd, and 3rd visit.
2nd visit 3rd visit
Number % Number %
38 76 46 92
8 16 4 8
4 8 0 0
50 100 50 100
0.077 0.001
Table 3 Asthma control level in regular treatment group comparing 1st, 2nd, and 3rd visit.
Cases on regular treatment
1st visit 2nd visit 3rd visit
Number % Number % Number %
Controlled 8 16 30 60 42 84
Partial controlled 20 40 18 36 8 16
Uncontrolled 22 44 2 4 0 0
Total 50 100 50 100 50 100
P value 0.043 0.042
Table 4 Level of asthma control, comparison between two groups in the three visits.
1st visit 2nd visit 3rd visit
1st group 2nd group 1st group 2nd group 1st group 2nd group
Number % Number % Number % Number % Number % Number %
Controlled 6 12 8 16 34 68 30 60 46 92 42 84
Partial controlled 18 36 20 40 12 24 18 36 4 8 8 16
Uncontrolled 26 52 22 44 4 8 2 4 0 0 0 0
Total 50 100 50 100 50 100 50 100 50 100 50 100
P value 0.16 0.319 0.222
Table 5 Acute attacks during study.
Number of attacks Number of patients with acute attacks
Carbamazepine group Regular treatment group
Number % Number %
One attack 2 4 8 16
Two attacks 6 12 4 8
Three attacks 4 8 6 12
Total 12 24 18 36
Mean 1.5 ± 0.57 3.2 ± 0.68
P value 0.003
Table 6 The spirometric evaluation, comparison between two groups in 1st visit.
Spirometry Group 1 Group 2 P value
Mean 1st visit FEV1 55.4 ± 15.333 53.24 ± 28.04 0.16
Mean 1st visit FVC 76.68 ± 14.607 75.8 ± 36.11 0.23
Mean 1st visit FEV1/FVC 72.24 ± 13.196 70.23 ± 17.148 0.26
Mean 1st visit PEF 36.44 ± 13.75 34.52 ± 17.436 0.13
Mean 1st visit FEF 25–75 31.56 ± 14.459 33.76 ± 26.247 0.10
Table 7 The spirometric evaluation, comparison between two groups in 2nd visit.
Spirometry Group 1 Group 2 P value
Mean 2nd visit FEV1 59.64 ± 11.567 54.24 ± 25.94 0.003
Mean 2nd visit FVC 78.4 ± 14.953 73.4 ± 34.30 0.001
Mean 2nd visit FEV1/FVC 76.32 ± 8.637 73.89 ± 17.79 0.071
Mean 2nd visit PEF 39.88 ± 11.957 32.62 ± 18.615 0.002
Mean 2nd visit FEF 25–75 38.08 ± 12.806 34.8 ± 26.601 0.021
18 M.S. Badawy et al.also plays a major role on pathogenesis of these diseases [10].
Of course, asthma is not only ‘‘bronchial seizure’’, or ‘‘partial
bronchial seizure’’ this is very simpliﬁed vision of problem, butit seems real that neurogenic paroxysmal and inﬂammatory
mechanisms play very important role in asthma sustaining as
a chronic disease [11].
Table 8 The spirometric evaluation, comparison between two groups in 3rd visit.
Spirometry Group 1 Group 2 P value
Mean 3rd visit FEV1 57.04 ± 10.876 50.81 ± 26.653 0.002
Mean 3rd visit FVC 77.68 ± 12.615 70.63 ± 34.685 0.001
Mean 3rd visit FEV1/FVC 73.42 ± 10.217 71.93 ± 8.574 0.086
Mean 3rd visit PEF 37.22 ± 10.127 31.51 ± 17.463 0.01
Mean 3rd visit FEF 25–75 33.76 ± 12.106 38.41 ± 27.525 0.03
Table 9 Side effects reported among Carbamazepine group.
Reported side eﬀects Number %
No Side eﬀects 40 80
Dizziness 4 8
Itching 1 2
Headache 3 6
Somnolence 2 4
Total 50 100
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done to all the patients of the study. There were 2 cases
(4%) that had abnormal EEG and no cases had neurological
signs. In comparison to other works Lomia et al., [12] who re-
ported that their study included 46 adult asthmatic patients,
69.6% of them had EEG signs and 87% of them had neurolog-
ical signs [12]. The difference between two studies may be be-
cause of the following reasons: we exclude patients who had a
history of neurological and psychiatric diseases while in the la-
ter study they did not exclude them.
In the present study, among the Carbamazepine group
there were 38 cases (76%) that showed improvement after
3 months of treatment and after 6 months of treatment 46
cases (92%) showed improvement. This is in agreement with
the study done by Tchelidze et al., 2006 who reported that
among the Carbamazepine group which included 33 adult
asthmatic patients, 25 cases of them (75.8%) showed stable
remission after 3 months of treatment with Carbamazepine
[1]. Also it is in agreement with another study done in 2005
by Lomia et al., who reported that among the oxcarbazepine
group which included 32 adult asthmatic patients, 25 cases
of them (78%) showed no asthma symptoms after 3 months
of treatment with oxcarbazepine [12].
The result of our study is also approximately similar to a
third study reported by P. Platonov et al., 2004. According
to their study the Carbamazepine group included 14 adult
asthmatic patients, 10 cases of them (71%) showed improve-
ment after 3 months of treatment with Carbamazepine [3]. In
the present study, among the routine antiasthmatic therapy
group there were 30 cases (60%) that showed improvement
after 3 months of treatment and after 6 months of treatment
42 cases (84%) showed improvement. This is in contrary with
study done by Lomia et al., [12]. According to their study the
placebo group included 14 patients, all of them showed no
improvement [12].
The contrariety may be because patients in their study were
allowed to abandon any other previously prescribed routine
antiasthmatic treatment in case of asthma symptoms disap-
pearance lasted at least 1 month after beginning the trial
[12].As regards the improvement and control of asthma based
on the above mentioned data of our study, patients who re-
ceived Carbamazepine in addition to their routine antiasth-
matic therapy showed 16% improvement more than patients
who received only routine antiasthmatic therapy after
3 months and 8% improvement more after 6 months.
In the present study, among the Carbamazepine group
there were 12 cases (24%) that developed acute attacks during
6 months of treatment, while among the routine regular anti-
asthmatic therapy there were 18 cases (36%) that developed
acute attacks during 6 months of treatment. Acute attacks
among the Carbamazepine group are 12% less than among
the routine regular antiasthmatic therapy group. In compari-
son to the other works Platonov et al., 2004 who reported that
among the Carbamazepine group which included 14 adult
asthmatic patients, there was no asthmatic attack during
3 months of treatment [3].
The spirometric evaluation, comparison between two
groups in the second and third visit for assessment of patients
control and pulmonary function tests. The differences between
the two groups in the second and third visits were statistically
signiﬁcant with regard to the mean FEV1, the mean FVC, the
mean PEF and the mean FEF 25–75. While the differences be-
tween the two groups in the second and third visits were not
statistically signiﬁcant as regard to the mean FEV1/FVC.
In comparison to other works Lomia et al., 2005 who re-
ported in their study that among the oxcarbazepine group
which included 32 patients, there was increase in PEF and
FEV1 rates up to normal level after 3 months of therapy
[12]. Also in comparison to another study Platonov et al.,
2004 who reported that among the Carbamazepine group
which included 14 patients, there was a quite gradual increase
in the morning peak ﬂow rates during 4 weeks of the study
and reached calculated normal level at the end of 12th week
[3].
In the present study the side effects of Carbamazepine
administration were as follows: Dizziness in 4 cases (8%); itch-
ing in 1 case (2%); Somnolence in 2 cases (4%); and headache
in 3 cases (6%). This is in agreement with study done by Lomia
et al., 2005 who reported that among the oxcarbazepine group
which included 32 patients the side effects were as follows: diz-
ziness in 2 cases (6.3%); Somnolence in 1 case (3.12%);
HEADACHE in 2 cases (6.3%); Somnolence and headache
in 1 case (3.12%)[12]. In conclusion Carbamazepine is effective
in treatment and in achievement of better asthma control with
minimal side effect.
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